Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Bisnorcymserine (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; First in man
- 06 Jul 2017 Planned End Date changed from 3 Jul 2017 to 3 Jul 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 03 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.